We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Eurostars Grant Awarded to International Consortium
News

Eurostars Grant Awarded to International Consortium

Eurostars Grant Awarded to International Consortium
News

Eurostars Grant Awarded to International Consortium

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Eurostars Grant Awarded to International Consortium"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Abzena plc has announced that a grant for €1.9 million has been awarded under the Eurostars™ programme to a consortium that comprises its subsidiary, Antitope Limited, Dutch biopharmaceutical companies Prothix BV and Aristi Biotech BV, the University Medical Center Utrecht (UMCU, the Netherlands) and GenOway, a French company.

The consortium is developing a novel treatment for clotting disorders, targeting antithrombin III, a protein which inhibits blood clotting. Members will provide their know-how and expertise to produce humanized monoclonal antibody candidates that bind antithrombin III, undertake preclinical proof of concept studies and develop a cell line for the manufacture of the selected lead candidate. This novel antibody has the potential to both prevent and treat bleeding in patients with disorders such as haemophilia.

Neil Butt, VP Business Development, Abzena, said: “Applying our Composite Human Antibody™ technology to this novel product will help produce a less immunogenic version, giving it a greater chance of improving the lives of patients.”

René Verdonk, CEO, Prothix, commented: “We are very pleased to have been awarded another Eurostars™ grant to develop a product that could prevent severe bleeding in patients with haemophilia and look forward to working with the other consortium members again.”

Erik Hack, Professor of Immunology, UMCU, said: “This project not only emphasizes the value of the research work undertaken at UMCU, but also illustrates that valorization of research results is important to UMCU. We are excited to be part of a consortium and look forward to seeing the preclinical proof of concept for this novel approach.”

Mark de Boer, CEO, Aristi, said: "We are keen to be able to bring our expertise in the early stage manufacture of monoclonal antibodies to this programme and to be involved in its preclinical development”.

Alexandre Fraichard, CEO, GenOway, said “We are pleased to be able to add our expertise in the development of preclinical disease models to this consortium of organizations with complementary technologies that will enable the development of a novel therapeutic product to improve the lives of patients.”

Advertisement